Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist

被引：0
|
作者：
Abraham, W
Koren, M
Bichet, DG
Verbalis, JG
Klapholz, M
Selaru, P
Bakker-Arkema, RG
Rummel, SA
机构：
[1] Univ Cincinnati, Coll Med, Dept Cardiol, Cincinnati, OH USA
[2] Jacksonville Ctr Clin Res, Jacksonville, FL USA
[3] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada
[4] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[5] Univ Med & Dent New Jersey, Newark, NJ 07103 USA
[6] Warner Lambert Co, Parke Davis Pharmaceut Res Div, Ann Arbor, MI USA
来源：
EUROPEAN HEART JOURNAL | 2000年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1848
引用
收藏
页码：345 / 345
页数：1
相关论文
共 50 条
  • [31] Novel vasopressin V1A and V2 antagonist (Conivaptan) increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure
    Verbalis, JG
    Ghali, JK
    Gross, P
    Long, WA
    Smith, N
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S120 - S120
  • [32] Hemodynamic effects of short-term infusion of a vasopressin V1A/V2 receptor antagonist conivaptan in patients with chronic heart failure during submaximal exercise
    Balling, Louise
    Wolsk, Emil
    Hassager, Christian
    Boesgaard, Soren
    Goldsmith, Steven R.
    Gustafsson, Finn
    AMERICAN HEART JOURNAL, 2018, 203 : 101 - 104
  • [33] Efficacy and safety of oral conivaptan:: A V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia
    Ghali, Jalal K.
    Koren, Michael J.
    Taylor, James R.
    Brooks-Asplund, Esther
    Fan, Kaisheng
    Long, Walker A.
    Smith, Neila
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2145 - 2152
  • [34] Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist
    Gunnet, Joseph W.
    Wines, Pamela
    Xiang, Min
    Rybczynski, Philip
    Andrade-Gordon, Patricia
    de Garavilla, Lawrence
    Parry, Tom J.
    Cheung, Wai-man
    Minor, Lisa
    Demarest, Keith T.
    Maryanoff, Bruce E.
    Damiano, Bruce P.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 590 (1-3) : 333 - 342
  • [35] Renal effects of a novel dual acting V1a/V2 vasopressin receptor antagonist: comparison with furosemide
    Kolkhof, P.
    Stasch, J. P.
    Pook, E.
    Schmeck, C.
    Fuerstner, C.
    Albrecht-Kuepper, B.
    EUROPEAN HEART JOURNAL, 2011, 32 : 788 - 789
  • [36] Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors
    Mouillac, B
    Phalipou, S
    Cotte, N
    Balestre, MN
    Hibert, M
    Manning, M
    Barberis, C
    VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES, 1998, 449 : 359 - 361
  • [37] Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway
    Izumi, Yuichiro
    Nakayama, Yushi
    Mori, Tomohiko
    Miyazaki, Hiroki
    Inoue, Hideki
    Kohda, Yukimasa
    Inoue, Takeaki
    Nonoguchi, Hiroshi
    Tomita, Kimio
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 292 (05) : F1418 - F1426
  • [38] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
    Tahara, A
    Saito, M
    Sugimoto, T
    Tomura, Y
    Wada, K
    Kusayama, T
    Tsukada, J
    Ishii, N
    Yatsu, T
    Uchida, W
    Tanaka, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69
  • [39] Coupling between V1a and V2 vasopressin receptor transduction pathways.
    Klingler, C
    Barrault, MB
    Ancellin, N
    Morel, A
    Corman, B
    Friedlander, G
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A0103 - A0103
  • [40] Sucessfull treatment of EBV-associated SIADH with V2 receptor antagonist
    Grajecki, D. S.
    Haas, C. S.
    Hubold, C.
    Lehnert, H.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2013, 121 (03)
12345